Polymyositis in childhood is characterised by muscle weakness and is sometimes associated with skin changes (dermatomyositis): this entity is usually classified as a collagen-vascular disease. Although the aetiology of polymyositis remains unknown, there is substantial evidence to suggest the immunologic mechanisms contribute to the muscle and connective tissue injury.1 2 Treatment with prednisolone at several dose levels has been suggested.Y6
Cytotoxic chemotherapy is also often prescribed for patients with an unsatisfactory response to prednisolone.
Between 1967 and 1982, 14 patients with polymyositis were seen on our clinics. Three of the 14 (20%) did not benefit from prednisolone and were thought to be steroid resistant. One of the three died of cardiomyopathy seven years after the onset of the illness and in another, severe contractures occurred and use of a wheelchair became necessary. Although an improved prognosis in a series of patients with polymyositis in childhood treated with steroids has been reported,?5 we found severe residual symptoms in some children with this disease.
Materials and methods
Between 1967 and 1982, 14 children were studied at the Paediatric Departments of Kobe General and Kyoto University Hospitals. The data obtained are summarised in Tables 1 and 2 . The age of onset ranged between 2 and 14 years; mean age 5 years 5 months. The diagnosis of polymyositis was based on the clinical findings of muscle weakness and skin rash, and confirmation was obtained by either enzyme abnormality, a muscle biopsy showing evidence of inflammatory myositis, or an abnormal electromyogram. The duration of follow up was 3 years 2 months to 11 years 5 months. The initial regimen of prednisolone was 1-2 to 2-3 mg/kg/day. After four weeks, this dose was reduced, dependent upon improvement in the clinical status and reversal of enzyme abnormality. The dose of the steroid was decreased further to a maintenance level of 5 to 20 mg, on alternate days. On average, the total treatment period was 3 years 6 months. Three of the 14 patients (cases 2, 10, and 13) were resistant to steroid and were given alternative treatment.
The grading system used for disability was the one employed by Rose furosemide. There was an initial favourable response to this regimen, but congestive cardiac failure ensued and she died at the age of 10 vears 10 months.
Discussion
Polvmyositis is thought to have an autoimmune basis and at present a cell mediated autoimmune reaction is widely held to be responsible for this disease.' Treatment with corticosteroids does improve the prognosis:i-6 11 12 the death rate has been reduced from around 33% to less than 10% with this management.3 4 11 Some children, however, are refractory to steroid treatment, and for these treatment with immunosuppressive agents, or more recently, a series of plasmapheresis has been recommended.7-9 13-l The suggested dose of prednisolone is 2 mg/kg/day,3 although Dubowitzs and Miller et al6 have proposed that a low dose of prednisolone is effective.5 6 We tried low dosage prednisolone treatment on the second admission in the patient case 2, but he did not respond well. We then employed 2 mg/kg/day of prednisolone and were able to induce the second remission (Fig. 2) .
Polymyositis in association with other connective tissue disorders is generally less likelv to respond to steroid treatment than the uncomplicated disease.8 In our series, cases 13 and 10 are thought to have dermatomyositis in association with progressive systemic sclerosis and rheumatoid arthritis, respectively, and little or no improvement occurred with steroid treatment in these two. On the other hand, although case 2 has uncomplicated polymyositis, he responded only partially to steroid and immunosuppressive drugs.
There are recent reports of patients with polymyositis refractory to immunosuppressive treatment who improved with plasmapheresis, suggesting the involvement of a circulating factor, such as autoantibody or immune complexes in the production of muscle lesions.'4 We examined circulating immune complexes with solid phase Clq binding assays in case 2 and found a slightly raised concentration once only. As cytotoxic reactivity has been experimentally shown in lymphocytes from patients with polymyositis against cultures of skeletal muscle cells, we prescribed lympho-plasmapheresis for this patient, in addition to cytotoxic immunosuppressive treatment-this led to some clinical improvement.
Cardiac involvement in adult and childhood polymyositis is an uncommon occurrence. 17 Electrocardiographic evidence of pericarditis, myocarditis, and arrhythmias has been reported.'7 Histological changes of fibrosis and sarcolemmic degeneration in cardiac and skeletal muscle are identical, and fibrosis of the cardiac conducting system can lead to progressive cardiac conduction defects.'^2' The patient in case 13 died of congestive heart failure 7 years from the onset of muscle weakness. The persistence of raised creatine phosphokinase activity in this patient indicated continuing progression of the underlying disease process, and the long term prognosis was unfavourable. Thus, cardiac involvement in those with polymyositis can become clinically overt if the disease persists, and the inflammatory or degenerative myocardial status may precipitate a variety of cardiac conduction defects. 22 Patients with polymyositis refractory to steroid should, therefore, be treated with alternative forms of therapy.
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Hammersmith Hospital, London The three patients with steroid resistant dermatomyositis documented by Drs Yoshioka, Okuno, and Mikawa are all highly atypical of the usual childhood dermatomyositis, as the authors themselves point out. In two of them there was evidence of other collagen disease-systemic sclerosis (case 13) and rheumatoid arthritis (case 10). The remaining patient (case 2) had what sounds like a more classic dermatomyositis, but his response to prednisolone was odd. Usually there is evidence of clinical response in the way of improved general well being and loss of the characteristic misery, and improvement in muscle function within two to four weeks of starting treatment and the creatine phosphokinase activity, if initially raised (which only occurs in about half the cases), often lags behind, remaining raised at times, even after complete clinical resolution with tailing of steroids. For this reason the clinical course is a much more reliable guide to reducing treatment than the creatine phosphokinase activity. In their case 2, the response was completely paradoxical with a precipitous fall in the creatine phosphokinase activity without any apparent clinical improvement. Although steroid has a direct influence on creatine phosphokinase activity, it seems unlikely one could ascribe so noticeable a fall to a non-specific steroid effect. All steroids are likely to cause a steroid myopathy, but the 9-a-fluoro steroids even more so; so that their use of betamethasone would normally be contraindicated as a drug of choice for dermatomyositis.
With increasing build up of cytotoxic treatment in addition to continuing steroid this patient eventually showed some response. It is often assumed that lack of response to increasing treatment (or high dose initial treatment) indicates unresponsiveness, but the alternative possibility of iatrogenic steroid myopathy as a result of overtreatment is equally likely. This was well illustrated by the recent case of an 11 year old girl referred to me with refractory dermatomyositis, who had initially responded well to treatment but subsequently became resistant to increasing doses of steroids with associated increasing generalised weakness together with swallowing and respiratory difficulties. She had become bed bound for 6 weeks and was considered to be terminal. She was on 70 mg prednisolone/day and had severe painful osteoporosis of her spine which made it almost impossible to move her. Over a period of five months we were able to gradually wean her off the steroids and get her ambulant again and as we reduced the steroids her strength steadily improved.
In the series of 29 of our personal cases reviewed by Miller et all the group of patients having a low dosage of prednisolone initially had fewer relapses and less morbidity and were on steroids for a shorter period of time than those receiving higher dosage. Six of the 10 cases in the low dosage group made an uncomplicated recovery and were off treatment at least a year compared with only 1 of 18 in the second group, although the initial severity of the groups seemed comparable. Of the 12 patients in group 2 off steroids there were more severe problems with calcinosis and contractures and four were severely incapacitated. Childhood dermatomyositis is almost uniformly responsive to steroid treatment. I think there is a good chance of remission with minimal risk of secondary complications from treatment with an initial low dosage schedule of prednisolone of I mg/kg daily and a reduction as soon as there is definite sign of clinical improvement (usually within two to four weeks) either in general wellbeing and loss of misery, or in increase in muscle power. This should be done very gradually and tailored to the needs of each patient, who should be closely monitored. In a 30 kg child, for example, I would start on 30 mg prednisolone/day and reduce by 5 mg/day at two weekly intervals till 20 mg/day and then by 2-5 mg/day at two weekly intervals till 10 mg/day and then by 1 mg/day at two weekly intervals. If at any point there is a suggestion of deterioration, manifesting itself either as increasing weakness or general misery, one should go back one step in the treatment and perhaps wait an extra two weeks before reducing this, or reduce at half the rate (alternate days instead of each day).
I reserve the use of additional drugs such as azathioprine, methotrexate, or cyclophosphamide for patients who are either incompletely responsive to steroid or who are difficult to wean off steroids. Alternate day steroid treatment is less effective and much slower for initial induction and should be 
